Characterization of N-terminally mutated cardiac Na+ channels associated with long QT syndrome 3 and Brugada syndrome by Christian Gütter et al.
ORIGINAL RESEARCH ARTICLE
published: 26 June 2013
doi: 10.3389/fphys.2013.00153
Characterization of N-terminally mutated cardiac Na+
channels associated with long QT syndrome 3 and
Brugada syndrome
Christian Gütter , Klaus Benndorf and Thomas Zimmer*
Institute of Physiology II, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany
Edited by:
Christopher Huang, University of
Cambridge, UK
Reviewed by:
Christopher Huang, University of
Cambridge, UK
Ming Lei, University of Manchester,
UK
*Correspondence:
Thomas Zimmer, Institute of
Physiology II, University Hospital
Jena, Friedrich Schiller University
Jena, Kollegiengasse 9,
07743 Jena, Germany
e-mail: thomas.zimmer@
mti.uni-jena.de
Mutations in SCN5A, the gene encoding the cardiac voltage-gated Na+ channel hNav1.5,
can result in life-threatening arrhythmias including long QT syndrome 3 (LQT3) and
Brugada syndrome (BrS). Numerous mutant hNav1.5 channels have been characterized
upon heterologous expression and patch-clamp recordings during the last decade. These
studies revealed functionally important regions in hNav1.5 and provided insight into
gain-of-function or loss-of-function channel defects underlying LQT3 or BrS, respectively.
The N-terminal region of hNav1.5, however, has not yet been investigated in detail,
although several mutations were reported in the literature. In the present study we
investigated three mutant channels, previously associated with LQT3 (G9V, R18W, V125L),
and six mutant channels, associated with BrS (R18Q, R27H, G35S, V95I, R104Q, K126E).
We applied both the two-microelectrode voltage clamp technique, using cRNA-injected
Xenopus oocytes, and the whole-cell patch clamp technique using transfected HEK293
cells. Surprisingly, four out of the nine mutations did not affect channel properties.
Gain-of-function, as typically observed in LQT3 mutant channels, was observed only in
R18W and V125L, whereas loss-of-function, frequently found in BrS mutants, was found
only in R27H, R104Q, and K126E. Our results indicate that the hNav1.5 N-terminus plays
an important role for channel kinetics and stability. At the same time, we suggest that
additional mechanisms, as e.g., disturbed interactions of the Na+ channel N-terminus with
other proteins, contribute to severe clinical phenotypes.
Keywords: cardiac sodium channel, cardiac arrhythmia, SCN5A channelopathies, electrophysiology, Long QT
syndrome, Brugada syndrome, N-terminus
INTRODUCTION
Voltage-gated sodium (Na+) channels are responsible for the
rapid upstroke of the action potential in electrically excitable
cells. The tetrodotoxin (TTX) resistant isoform hNav1.5, encoded
by the SCN5A gene, is the predominant isoform in the human
heart (Gellens et al., 1992; Blechschmidt et al., 2008; Zimmer,
2010; Rook et al., 2012; Savio-Galimberti et al., 2012). A broad
spectrum of mutations in SCN5A were related to a variety of
inherited cardiac diseases, such as long QT syndrome type 3
(LQT3), Brugada syndrome (BrS), cardiac conduction disease
(CCD), or sick sinus syndrome (SSS) (Zimmer and Surber,
2008; Gui et al., 2010). Heterologous expression of respective
mutant hNav1.5 channels revealed important insight into the
mechanisms underlying these cardiac diseases. In LQT3, mutant
channels are characterized by gain-of-function features, like faster
recovery from the inactivated state (Chandra et al., 1998; Clancy
et al., 2003), inactivation defects (Bennett et al., 1995; Chandra
et al., 1998), or dispersed reopenings from the inactivated state
(Dumaine et al., 1996). Such defects are believed to result in
an action potential widening and consequently, in the observed
QT prolongation. In BrS or CCD, mutant channels often show
loss-of-function features, like reduced channel availability at the
resting membrane potential (Rivolta et al., 2001), a positive shift
of steady-state activation (Vatta et al., 2002a; Potet et al., 2003),
impaired trafficking to the plasma membrane (Baroudi et al.,
2001; Valdivia et al., 2004), or the inability to conduct Na+ (Kyndt
et al., 2001; Zhang et al., 2008). Such defects can explain cardiac
conduction abnormalities and the observed ST segment eleva-
tion (Alings andWilde, 1999; Yan and Antzelevitch, 1999). These
genotype-phenotype associations in SCN5A channelopathies are
not only important for clinicians regarding the management of
genotype-positive patients and symptom-free family members.
Functional data onmutant channels also extended our knowledge
about important structural elements in the cardiac Na+ channel,
like the DIII-DIV linker as the inactivation gate (Bennett et al.,
1995) or position 1053 for ankyrin-G binding (Mohler et al.,
2004).
Currently, however, we are faced with a growing number of
mutations that are not yet characterized by electrophysiologi-
cal measurements. The lack of functional data makes it difficult
for clinicians to interpret the results of genetic testing, because
a rare deviation from the published SCN5A sequence could
be malign or even benign. For example, only 20% of the BrS
patients are SCN5A-positive cases, and the majority of BrS-
causative mutations or factors still remain obscure (Kapplinger
et al., 2010). Consequently, the same yet unknown factors could
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be also crucial for the manifestation of the disease in SCN5A-
positive BrS patients, in particular when mutant channels were
either not characterized or electrophysiologically indiscernible
from wild-type hNav1.5.
The present study focuses on nine arrhythmia-causing mis-
sense mutations localized to the N-terminus of hNav1.5 that
have not yet been characterized by electrophysiological tech-
niques (Figure 1). We selected all three published LQT3 muta-
tions and six out of seventeen BrS mutations reported in the
online database of Drs. Priori and Napolitano (http://www.fsm.
it/cardmoc/). The aim of this project was to establish respective
genotype-phenotype correlations and to get more insight into the
role of the intracellularly exposed N-terminus for channel gat-
ing. This region has not yet been investigated in detail in terms of
structure-function relationships. Therefore, it was challenging for
us to search for possible inactivation defects in the LQT3 mutant
channels, and for loss-of-function features caused by the BrS mis-
sense mutations. All mutant channels were expressed in both
HEK293 cells and Xenopus oocytes. We performed electrophysi-
ological measurements in both heterologous hosts to identify or
exclude cell-specific effects.
MATERIAL AND METHODS
RECOMBINANT DNA PROCEDURES
Generation of the expression plasmid pTSV40G-hNav1.5, coding
for wild-type hNav1.5, was described previously (Walzik et al.,
2011). The original hH1 cDNA (accession number M77235)
was kindly provided by Dr. A. L. George (Gellens et al., 1992).
Mutations at amino acid positions 9, 18, 27, 35, 95, 104, 125, and
126 were introduced using the recombinant PCR technique and
the following internal primer pairs:
5′-TTACCTCGGGTCACCAGCAGCTTCCGCAGG-3′ and
5′-GGAAGCTGCTGGTGACCCGAGGTAATAGGAA
GTTTG-3′ to obtain G9V,
5′-GCAGGTTCACACTGGGAGTCCCTGGCAGCCATC-3′ and
5′-CCAGGGACTCCCATGTGAACCTGCGGAAGCTG-3′ to
obtain R18W,
5′-GCAGGTTCACACAGGAGTCCCTGGCAGCCATC-3′ and
5′-CCAGGGACTCCTGTGTGAACCTGCGGAAGCTG-3′ to
obtain R18Q,
5′-CATCGAGAAGCACATGGCGGAGAAGCAAGCCC-3′ and
5′-CTTCTCCGCCATGTGCTTCTCGATGGCTGCCAGG-3′ to
obtain R27H,
5′-AAGCAAGCCCGCAGCTCAACCACCTTGCAGGAG-3′ and
5′-GGTGGTTGAGCTGCGGGCTTGCTTCTCCGCCATG-3′ to
obtain G35S,
5′-AAGACTTTCATCATACTGAATAAAGGCAAGACCA-3′ and
5′-CCTTTATTCAGTATGATGAAAGTCTTTTGGGTG-3′ to
obtain V95I,
5′-ACCATCTTCCAGTTCAGTGCCACCAACGCCTT-3′ and
5′-TGGCACTGAACTGGAAGATGGTCTTGCCTTTA-3′ to
obtain R104Q,
5′-AGAGCGGCTTTGAAGATTCTGGTTCACTCG-3′ and
5′-GAACCAGAATCTTCAAAGCCGCTCTCCGGATGGG
GTGG-3′ to obtain V125L, and
5′-CGGCTGTGGAGATTCTGGTTCACTCGCTCTT-3′ and
5′-AGTGAACCAGAATCTCCACAGCCGCTCTCCGGAT
GGGGT-3′
to obtain K126E. The recombinant PCR products were inserted as
AgeI/HindIII fragments into the corresponding sites of pTSV40G-
hNav1.5. A thermostable DNA polymerase with proofreading
activity was used for all PCR reactions (Pfu DNA polymerase,
Promega, Madison, USA). The correctness of PCR-derived
sequences was confirmed by DNA sequencing. Construction of
the control plasmid encoding KPQ channels was previously
described (Surber et al., 2008). All channel variants were placed
under the control of the SV40 promoter in expression plasmid
pTSV40G, a derivative of pTracerSV40 (Invitrogen) (Camacho
et al., 2006). Vector pTSV40G contains the T7 promoter and,
in a separate expression cassette, the coding region of the
enhanced green fluorescent protein (EGFP; Clontech) to allow for
cRNA preparation and for selection of transfected HEK293 cells,
respectively.
HETEROLOGOUS EXPRESSION IN HEK293 CELLS
Heterologous expression in mammalian cells was done as pre-
viously described (Zimmer et al., 2002b). Human embryonic
kidney cells (HEK293 cell line, ATCC number CRL-1573)
were cultured in Dulbecco’s Modified Eagle Medium (DMEM;
GibcoBRL), supplemented with 2mM glutamine, 10% fetal
bovine serum, 100μg/ml streptomycin, 100 U/ml penicillin, and
0.25μg/ml amphotericin B. HEK293 cells were transfected by a
standard calcium phosphate precipitation method using 1.0μg
plasmid DNA per transfection dish (60mm diameter). After an
incubation time of 24 h, the transfection mixture was removed.
Cells were seeded onto poly-L-lysine coated glass cover slips and
cultured in fresh growth medium. Na+ currents were investigated
24–48 h after transfection.
PATCH-CLAMPMEASUREMENTS
Electrophysiological recordings were performed, as previously
described (Surber et al., 2008; Walzik et al., 2011). We used
an inverted microscope (Axiovert 100, Carl Zeiss Jena GmbH,
Germany) and an Axopatch 200B amplifier (Axon-Instruments,
Foster City, USA). All measurements were carried out at room
temperature (19–22◦C). The bath solution contained (mM):
140.0NaCl, 1.8 CaCl2, 1.0MgCl2, 10.0 glucose, 10.0 HEPES, pH
7.4 (CsOH). The pipette solution contained (mM): 10.0NaCl,
130.0 CsCl, 10.0 EGTA, 10.0 HEPES, pH 7.3 (CsOH). Currents
were elicited by test potentials from −80mV to 40mV in 5
or 10mV increments at a pulsing frequency of 1.0Hz (hold-
ing potential −120mV). Cells that produced a peak current
amplitude >6 nA were excluded from data analysis. Steady-state
activation (m∞) was evaluated by fitting the Boltzmann equation
m∞ = {1 + exp[−(V − Vm)/s]}−1 to the normalized conduc-
tance as function of voltage. Steady-state inactivation (h∞) was
determined with a double-pulse protocol consisting of 500ms
prepulses to voltages between −140 and −30mV followed by
a constant test pulse of 10ms duration to −20mV at a puls-
ing frequency of 0.5Hz. The amplitude of peak INa during the
test pulse was normalized to the maximum peak current and
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FIGURE 1 | Schematic representation of hNav1.5 and the N-terminal
mutations investigated in this study. (A) Proposed hNav1.5 topology.
Affected residues are indicated in white (LQT3) and light grey (BrS).
The schematic structure also highlights some important structural
features (DI to DIV—domain I to IV, IFM—residues isoleucine,
phenylalanine, and methionine of the inactivation gate, IQ—calmodulin
binding motif, EF—Ca++ binding EF hand domain). (B) Alignment of
the N-terminal sequences of human Nav1.1—Nav1.9. Mutations
associated with LQT3 or BrS are underlined or indicated in italics,
respectively. Most of the eight affected residues are conserved among
the Nav1 subfamily. Residues at position 35 are variable, and position
125 is occupied by isoleucine in all other human Na+ channels. All
eight residues affected by a SCN5A mutation are identical in Nav1.5
of human, rat, mouse, and dog (not shown). The N-terminal region of
the first putative membrane spanning segment DI-S1 is indicated in
light grey. References: G9V (Millat et al., 2006), R18W (Tester et al.,
2005), R18Q (Kapplinger et al., 2010), R27H (Priori et al., 2002), G35S
(Levy-Nissenbaum et al., 2001), V95I (Liang et al., 2006), R104Q
(Levy-Nissenbaum et al., 2001), V125L (Tester et al., 2005), K126E
(Vatta et al., 2002a).
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plotted as function of the prepulse potential. Data were fit-
ted to the Boltzmann equation h∞ = {1 + exp[(V − Vh)/s]}−1.
V is the test potential, Vm and Vh are the mid-activation and
mid-inactivation potentials, respectively, and s the slope factor
inmV. Glass pipettes were pulled from borosilicate glass. Glass
tips were heat polished by microforge MF 830 (Narishige, Japan).
The pipette resistance was between 1.4 and 2.6M. Series resis-
tance compensation was adjusted so that any oscillations were
avoided leaving at most 25% of the series resistance uncompen-
sated. Currents were on-line filtered with a cut-off frequency
of 10 kHz (4-pole Bessel). Recording and analysis of the data
was performed on a personal computer with the ISO3 soft-
ware (MFK, Niedernhausen, Germany). The sampling rate was
50 kHz. Student’s t-test was used to test for statistical significance.
Statistical significance was assumed for P < 0.05.
EXPRESSION IN Xenopus Laevis OOCYTES
Preparation of Xenopus laevis oocytes, in vitro transcription,
and cRNA injection was done as previously described (Zimmer
et al., 2002a). Fluorescence intensities of the cRNA bands were
measured using the gel documentation system from Herolab
(Wiesloch, Germany). Concentrations of the cRNA variants
were adjusted to ∼ 0.01μg/μl, before injecting about 50–80 nl
cRNA per oocyte. After 3 days incubation at 18◦C in Barth
medium, the peak current amplitude of the whole-cell Na+ cur-
rent was between 0.5 and 8.0μA, depending on the quality of
the oocyte batch. Cells producing currents larger than 5μA were
not selected for data evaluation. Measurements were performed
in at least four different batches of oocytes. For the measure-
ments of persistent Na+ currents we injected undiluted cRNA
preparations (∼ 0.2μg/μl) in order to increase this small current
fraction. This resulted in transient Na+ currents>8μA in 96mM
external Na+.
TWO-MICROELECTRODE VOLTAGE-CLAMP TECHNIQUE
Whole-cell Na+ currents were recorded with the two-
microelectrode voltage-clamp technique, similarly as previously
described (Zimmer et al., 2002a). For all recordings we used the
amplifier TEC-05-S (npi electronic GmbH, Tamm, Germany).
For the determination of peak current amplitudes, steady-
state activation, steady-state inactivation and recovery from
inactivation, the following bath solution was used (in mM):
96NaCl, 2 KCl, 1.8 CaCl2, 1MgCl2, 10 HEPES/KOH, pH 7.4.
The persistent current fraction was determined as previously
described (Surber et al., 2008): First, we measured the inward
current at the end of a 200ms test pulse that could be blocked
by 10μM TTX in 96mM external Na+ (Ipersistent). Then, we
reduced the extracellular Na+ concentration to 20mM in
order to insure adequate voltage control also for the first few
milliseconds of the test pulse and determined the peak current
amplitude in the same oocyte (Itransient). The following bath
solution was used (in mM): 20NaCl, 78 KCl, 1.8CaCl2, 1MgCl2,
10 HEPES/KOH, pH 7.4. Currents were elicited by 200ms test
potentials from −80 to 40mV in 5mV or 10mV increments
(holding potential −120mV, pulsing frequency 1.0Hz).
RESULTS
PROPERTIES OF LQT3 MUTANT CHANNELS (G9V, R18W, V125L)
All three mutant channels associated with LQT3 generated whole-
cell currents comparable to those observed for hNav1.5 (Table 1,
Figure 2A). No significant differences were observed in the peak
current density when expressing G9V, R18W and V125L in
HEK293 cells or in Xenopus oocytes. Also, the persistent cur-
rent fraction was not increased in both expression systems
(Table 1, Figure 2B), which is in contrast to mutantKPQ chan-
nels that were included as a positive control. When analyzing
channel inactivation by fitting the Na+ current decay using a
Table 1 | Peak current densities and persistent currents in HEK293 and Xenopus laevis oocytes.
Channel HEK239 cells Xenopus laevis oocytes
Peak current density Ipersistent/I transient Normalized peak current Ipersistent/I transienta
at −25mV (pA/pF) n at −20mV (%) n at −20mV n at −30mV (%) at −10mV (%) n
CONTROL
hNav1.5 193± 12 90 0.22± 0.09 5 1.00± 0.04 92 0.83± 0.10 1.27± 0.23 18
LQT3
G9V 200± 33 11 0.25± 0.15 4 1.29± 0.23 26 1.45± 0.30 1.88± 0.29 12
R18W 260 ± 36 14 0.19 ± 0.07 4 0.84 ± 0.07 27 1.52 ± 0.70 1.20 ± 0.40 4
V125L 161 ± 28 21 0.08 ± 0.05 4 1.08 ± 0.16 36 1.28 ± 0.36 1.10 ± 0.38 6
BrS
R18Q 175 ± 21 19 n.d. − 1.26 ± 0.18 23 n.d. n.d. −
R27H 159 ± 20 18 n.d. − 1.51 ± 0.36 19 n.d. n.d. −
G35S 224 ± 35 11 n.d. − 1.09 ± 0.12 20 n.d. n.d. −
V95I 205 ± 15 20 n.d. − 0.88 ± 0.15 23 n.d. n.d. −
R104Q No current 10 n.d. − 0.29± 0.02* 45 n.d. n.d. −
K126E 172 ± 20 24 n.d. − 1.13 ± 0.09 36 n.d. n.d. −
aIpersistent /Itransient ratios in KPQ channels: 10.4 ± 2.1 % at −30mV, 12.8 ± 2.9 % at −10mV (n = 8).
* indicates p < 0.05 vs. hNav1.5.
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FIGURE 2 | Whole-cell Na+ currents upon expression in HEK293 of
hNav1.5 mutant channels associated with LQT3. (A) Current families.
Currents were elicited by test potentials from −80mV to various test
pulses in 5 or 10mV increments at a pulsing frequency of 1.0Hz. (B)
Persistent currents at −20mV. The non-inactivating current fraction was
similarly small in both wild-type and mutant hNav1.5 channels. For
individual values see Table 1. Mutant KQP channels were used as a
positive control.
mono-exponential function, we observed a slower inactivation at
more negative test potentials in R18W and V125L (Figure 3A).
Respective inactivation time constants τh were significantly
increased at −50mV (R18W: τh = 11.5 ± 2.2, n = 12; V125L:
τh = 9.9 ± 1.4, n = 14; hNav1.5: τh = 6.3 ± 0.4, n = 55).
Steady-state activation remained unchanged in all LQT3
mutant channels. Mid-activation potentials Vm were not signifi-
cantly different from hNav1.5 values in HEK293 cells andXenopus
oocytes (Tables 2, 3). Similarly, no differences were observed in
channel availability, except for V125L in HEK293 cells (Table 2,
Figure 3B). The respective mid-inactivation potential Vh was
shifted by 3.1mV into depolarized direction, when compared
to wild-type channels. As a consequence, the window current
resulting from the small overlap of the steady-state activation
and steady-state inactivation curves should be increased in V125L
(Figure 3C). Interestingly, this effect was not seen in the oocyte
system: Mid-inactivation potentials were neither altered in V125L
nor in the other two LQT3 mutant channels G9V and R18W
(Table 3). When analyzing the recovery from inactivation in
HEK293 cells using a double pulse protocol we noticed an accel-
erated recovery in V125L (Figure 3D). The fast time constant τf
was significantly smaller and the corresponding amplitude Af was
increased (Table 2). This effect of the mutation at position 125 on
recovery from inactivation was not observed in the oocyte sys-
tem: Recovery time constants and the corresponding amplitudes
were similar in all three LQT3 mutant channels, when compared
to hNav1.5 data (Table 3).
In conclusion, G9V channels were indistinguishable from
wild-type hNav1.5. R18W showed a decelerated current decay,
similarly as seen in some other LQT3 mutant channels (see
section Discussion). V125L was characterized by the most severe
defects (slower inactivation, increased window current and faster
recovery from inactivation). Moreover, our data show that the
gain-of-function defects in V125L, typically seen in LQT3 mutant
channels, became manifest only in the mammalian expression
system.
PROPERTIES OF BrS MUTANT CHANNELS (R18Q, R27H, G35S, V95I,
R104Q, K126E)
Expression of a great number of mutated Na+ channel variants,
associated with BrS, results either in a significant peak current
reduction or even in non-functional channels. Surprisingly, when
expressing the six N-terminallymutated variants in HEK293 cells,
we did not observe a current reduction in five of them (Table 1,
Figure 4). R18Q, R27H, G35S, V95I, andK126E generated whole-
cell currents that were comparable to those observed for hNav1.5.
Expression of R104Q did not result in functional channels in
HEK293 cells (Figure 4). Interestingly, when injecting Xenopus
oocytes with cRNA for this mutant variant, typical Na+ inward
currents were observed, but peak currents were reduced to 29%
compared to hNav1.5 (Table 1).
In HEK293 cells, two out of the five functional mutant chan-
nels were characterized by a positive shift of the steady-state
activation relationship. In R27H and K126E, the mid-activation
potential Vm was shifted by 4.0mV and 2.8mV, respectively, and
in R27H, the slope was significantly increased (Table 2, Figure 5).
This shift in R27H and K126E was accompanied by a respectively
slower channel inactivation at less depolarized membrane poten-
tials (Figure 5A). Steady-state activation and inactivation time
constants in R18Q, G35S and V95I were unchanged compared
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FIGURE 3 | Electrophysiological properties in HEK293 cells of mutant
hNav1.5 channels associated with LQT3. (A) Inactivation time constants τh
(ms) as function of voltage. At −50mV both R18W and V125L channels
inactivated more slowly compared to hNav1.5 (∗ indicates p < 0.05). G9V
channel inactivation was indistinguishable from hNav1.5 (data not shown).
(B) Steady-state activation and inactivation in V125L channels. The figure
shows the mean of 4 representative measurements for each. (C) Window
current in hNav1.5 (grey area, solid lines) and V125L (dark grey area, dotted
lines). (D) Recovery from inactivation was accelerated in V125L (∗ indicates
p < 0.05 vs. hNav1.5). For individual values see Table 2.
Table 2 | Electrophysiological properties of mutant hNav1.5 channels in HEK293 cells.
Channel Steady-state activation Steady-state inactivation Recovery from inactivation
s (mV) Vm (mV) n s (mV) Vh (mV) n τf (ms) Af τs (ms) As n
CONTROL
hNav1.5 5.7 ± 0.1 −35.1± 0.4 88 5.9 ± 0.1 −84.3± 0.6 68 5.8 ± 0.3 0.84 ± 0.01 110 ± 17 0.16 ± 0.04 40
LQT3
G9V 5.7 ± 0.4 −33.8± 1.3 11 6.0 ± 0.1 −84.2± 2.0 8 5.4 ± 0.7 0.81 ± 0.04 60.0 ± 9 0.19 ± 0.03 6
R18W 5.6 ± 0.3 −35.3± 2.2 13 5.6 ± 0.2 −83.0± 2.4 9 4.8 ± 0.5 0.83 ± 0.05 70.0 ± 24 0.17 ± 0.04 5
V125L 5.6 ± 0.2 −34.4± 1.0 21 5.6 ± 0.1 −81.2± 0.9* 20 4.8± 0.3* 0.88± 0.01* 128 ± 22 0.12± 0.01* 18
BrS
R18Q 5.7 ± 0.2 −34.6± 1.1 18 5.7 ± 0.2 −82.1± 1.0 16 5.0 ± 0.5 0.82 ± 0.04 52.0 ± 6 0.18 ± 0.03 10
R27H 6.8± 0.2* −31.1± 1.0* 18 5.8 ± 0.2 −84.7± 1.2 14 6.4 ± 0.6 0.77± 0.03* 111 ± 26 0.23± 0.03* 12
G35S 5.4 ± 0.4 −36.8± 1.5 10 5.4 ± 0.1 −86.1± 1.3 9 4.7 ± 0.4 0.85 ± 0.01 91.0 ± 23 0.15 ± 0.01 7
V95I 6.0 ± 0.2 −33.9± 0.9 20 5.5 ± 0.1 −83.3± 1.3 15 5.7 ± 0.6 0.83 ± 0.02 60.0 ± 11 0.17 ± 0.02 9
K126E 5.9 ± 0.3 −32.3± 1.1* 21 5.9 ± 0.1 −80.9± 0.9* 21 5.2 ± 0.5 0.86 ± 0.02 91.0 ± 23 0.14 ± 0.02 13
* indicates p < 0.05 vs. hNav1.5.
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Table 3 | Electrophysiological properties of mutant hNav1.5 channels in Xenopus laevis oocytes.
Channel Steady-state activation Steady-state inactivation Recovery from inactivation
s (mV) Vm (mV) n s (mV) Vh (mV) n τf (ms) Af τs (ms) As n
CONTROL
hNav1.5 3.6 ± 0.1 −33.5± 0.4 82 5.4 ± 0.1 −71.2± 0.7 28 3.8 ± 0.1 0.93 ± 0.01 399 ± 50 0.07 ± 0.006 48
LQT3
G9V 3.5 ± 0.2 −33.4± 0.6 6 5.2 ± 0.2 −71.3± 0.9 9 3.9 ± 0.3 0.93 ± 0.02 339 ± 64 0.07 ± 0.012 12
R18W 3.6 ± 0.2 −33.8± 1.0 6 4.9 ± 0.1 −72.1± 1.2 5 4.4 ± 0.4 0.94 ± 0.01 281 ± 48 0.06 ± 0.008 13
V125L 3.8 ± 0.2 −32.9± 0.6 25 5.2 ± 0.2 −74.5± 1.9 8 3.9 ± 0.3 0.93 ± 0.04 283 ± 64 0.07 ± 0.011 9
BrS
R18Q 3.8 ± 0.1 −32.3± 1.6 12 5.5 ± 0.1 −70.6± 1.1 11 3.4 ± 0.3 0.93 ± 0.02 236 ± 53 0.07 ± 0.013 11
R27H 3.6 ± 0.1 −32.5± 0.9 26 5.5 ± 0.2 −72.2± 1.1 6 3.8 ± 0.6 0.91 ± 0.05 505 ± 182 0.09 ± 0.018 5
G35S 3.7 ± 0.2 −33.8± 0.8 10 5.2 ± 0.1 −73.3± 1.0 9 4.2 ± 0.2 0.92 ± 0.01 452 ± 97 0.08 ± 0.013 14
V95I 3.8 ± 0.3 −31.6± 2.4 6 5.1 ± 0.1 −71.6± 1.1 11 3.3 ± 0.1 0.90 ± 0.01 134 ± 35 0.10 ± 0.009 5
R104Q 3.9 ± 0.2 −34.0± 0.8 7 5.6 ± 0.3 −73.8± 0.5* 6 4.6 ± 0.1* 0.92 ± 0.02 344 ± 125 0.08 ± 0.012 12
K126E 3.7 ± 0.1 −32.9± 0.8 24 4.9 ± 0.1 −70.0± 0.8 9 3.1 ± 0.2 0.91 ± 0.04 105 ± 32 0.09 ± 0.009 6
* indicates p < 0.05 vs. hNav1.5.
FIGURE 4 | Whole-cell Na+ currents upon expression in HEK293 of
hNav1.5 mutant channels associated with BrS. Currents were elicited
from −80mV to various test pulses in 5 or 10mV increments at a pulsing
frequency of 1.0Hz (holding potential −120mV). For average peak current
densities see Table 1. Expression of R104Q did not result in functional
channels in the mammalian expression system.
to hNav1.5 (Table 2). Analyzing steady-state inactivation in the
mammalian expression system, we observed only an increased
availability in K126E: The correspondingmid-inactivation poten-
tial Vh was by 3.4mV more positive compared to hNav1.5
(Table 2, Figure 5B). Time constants for recovery from inactiva-
tion were not significantly altered in the BrS mutant channels.
We only noticed a decreased amplitude of the fast recovery time
constant and an increased amplitude of the slow recovery time
constant in R27H.
When analyzing our oocyte recordings with the BrS mutant
channels, we were very surprised that the electrophysiological
parameters for steady-state activation, steady-state inactivation,
and recovery from inactivation were statistically indistinguish-
able from those seen in hNav1.5 (Table 3). None of the loss-
of-function defects, observed in R27H and K126E channels in
HEK293 cells, were observed in the oocyte expression system.
Functional expression of R104Q inXenopus oocytes allowed us
to determine the electrophysiological properties of these mutant
channels (Table 3). In addition to reduced peak current densi-
ties, we observed a significant reduction in channel availability
(Figure 6). The mid-inactivation potential was shifted by 2.6mV
into the hyperpolarized direction (see Vh values in Table 3). At
the same time, recovery from inactivation was decelerated in
R104Q (Table 3, Figure 6C). Steady-state activation and inactiva-
tion time constants remained unchanged when compared to the
corresponding hNav1.5 data.
In conclusion, expression of R18Q, G35S, and V95I inHEK293
and Xenopus oocytes did not reveal any of the loss-of-function
features typically observed in BrS mutant channels. In HEK293
cells, R27H and K126E were characterized by positively shifted
steady-state activation curves, a result that is in agreement with a
BrS phenotype (Clancy and Kass, 2002). R104Q was not func-
tional in HEK293 cells, whereas in Xenopus oocytes we found
functional expression but the current amplitude was significantly
diminished and the recovery from inactivation was slowed. So
it seems that, similarly to the LQT3 mutants, channel defects
are more pronounced in the mammalian than in the oocyte
expression system.
DISCUSSION
Our study on the nine N-terminally mutated cardiac Na+ chan-
nels revealed three main results: First, three mutations produced
gain-of-function or loss-of-function defects that are most likely
associated with LQT3 (V125L) or BrS (R104Q, R27H), respec-
tively. Second, most of the heterologously expressed channels
were either indistinguishable from wild-type hNav1.5 or charac-
terized by only marginally altered electrophysiological properties.
And third, in order to detect alterations of the electrophysiological
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FIGURE 5 | Electrophysiological properties in HEK293 cells of mutant
hNav1.5 channels associated with BrS. (A) Inactivation time constants τh
(ms) as function of voltage. K126E channels inactivated more slowly at
−50mV (∗∗), R27H inactivated more slowly from −50 to −25mV (∗), when
compared to hNav1.5. R18Q, G35S, and V95I channels were indistinguishable
from hNav1.5 (data not shown). (B) Steady-state activation and steady-state
inactivation curves. Mid-activation potentials (Vm) were significantly shifted
towards depolarized potentials in both R27H and K126E. Mid-inactivation
potential Vh was shifted only in K126E. The figure was drawn using the mean
of 4 representative measurements for each. Vm and Vh of the other mutant
channels, R18Q, G35S and V95I, were indistinguishable from the respective
hNav1.5 values. For data and statistics see Table 2.
properties in mutant channels mammalian cells were superior to
Xenopus oocytes.
GENOTYPE-PHENOTYPE CORRELATIONS FOR LQT3 MUTANTS
Among the three LQT3 mutant channels investigated, the most
pronounced gain-of-function features were noticed in V125L.
Despite the absence of an increased persistent current fraction,
three other channel defects were observed (Figure 3). These
defects may synergistically prolong the cardiac action potential
and explain QTc interval prolongation in the patients (Tester
et al., 2005). In R18Wwe found only a slowing of open-state inac-
tivation at less depolarized membrane potentials. It is doubtful
that such a rather mild effect is sufficient to cause LQT3. A sim-
ilar genotype-phenotype disassociation was previously reported
in case of P1332L, a mutation that produced only mild chan-
nel defects, similarly as R18W (Ruan et al., 2007). P1332L was
found in two independent studies and all index patients were
kids with QTc values of up to 760ms (Kehl et al., 2004). At the
same time, other mutant channels characterized by a slower cur-
rent decay also produced a significant persistent current fraction,
like Y1795C channels (Rivolta et al., 2001), but patients did not
present such extremely prolonged QT intervals. It is further note-
worthy that R18Wwas identified in another study on BrS as a rare
control, but not as a mutation causing LQT3 (Kapplinger et al.,
2010). Together these observations strongly suggest that addi-
tional yet unknownmechanisms contribute to the ECG alteration
in R18W and P1332L carriers. G9V mutant channels were even
indistinguishable from wild-type hNav1.5. This was the most sur-
prising result, because glycine is highly conserved at this position
(Figure 1). One explanation for this obvious discrepancy between
our results and clinical data is that the 69 years old patient also
presented a homozygous KCNH2 polymorphism (T897 instead
of K897) (Millat et al., 2006). Future studies may answer the
question whether or not this rare polymorphism is capable of
modulating the cardiac action potential in G9V mutant carriers.
GENOTYPE-PHENOTYPECORRELATIONS FOR BrS MUTANTS
Among the six BrS mutant channels investigated in this study, the
most pronounced loss-of-function features were seen in R104Q.
Expression in HEK293 cells did not result in functional channels
suggesting SCN5A haploinsufficiency in R104Q carriers. Similar
results were obtained in a recent study on R104W (Clatot et al.,
2012). It is interesting to note that even successful expression in
Xenopus oocytes resulted in significant channel loss-of-function
(Figure 6). These data together suggest that position 104 is crucial
for Na+ channel expression and kinetics. The molecular mech-
anism leading to loss-of-function in R104Q is still unknown.
The lack of a Na+ current in R104Q-transfected cells could be
due to incorrect folding in the endoplasmic reticulum, impaired
post-translational modification, disturbed trafficking, enhanced
degradation, or defective gating and permeation in otherwise
correctly targeted channels. In R27H and K126E channels, we
observed a positive shift of the steady-state activation curve, simi-
larly as seen in other BrS mutants like A735V (Vatta et al., 2002b).
Such a shift is expected to decelerate upstroke velocity and cardiac
conduction, and thus may explain the observed ECG alterations
(Clancy and Kass, 2002; Priori et al., 2002). In K126E, this loss-
of-function feature was accompanied by an increased steady-state
availability, and thus by a potential gain-of-function feature, sug-
gesting additional yet unknown factors that contribute to BrS in
K126E carriers. Nevertheless, we think that the K126E is indeed
the primary cause of the disease. First, K126 is a conserved residue
and the mutation caused an exchange of a positive charge by a
negative amino acid. Second, K126E was detected in two unre-
lated patients (Vatta et al., 2002a; Kapplinger et al., 2010). And
third, a concomitant shift of both steady-state activation and
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FIGURE 6 | Electrophysiological properties of R104Q in Xenopus
oocytes. (A) Whole-cell Na+ currents. Peak current amplitudes were
significantly reduced in R104Q (see Table 1). Currents were elicited from
−80mV to various test pulses in 5 or 10mV increments at a pulsing
frequency of 1.0Hz (holding potential −120mV). (B) Steady-state activation
and inactivation curves. In R104Q, steady-state availability was significantly
reduced. (C) Recovery from inactivation was slower in R104Q (∗ indicates
p < 0.05 vs. hNav1.5). For individual values see Table 3.
inactivation curves was also reported for other BrS mutant chan-
nels, like N406S (Itoh et al., 2005) and delK1479 (Zhang et al.,
2007).
In R18Q, G35S, and V95I we could not detect any functional
defect (Tables 2, 3), and the pathogenicmechanism leading to BrS
remains to be investigated. At least V95 is highly conserved, and it
is reasonable to assume that the mutation at this position is corre-
lated to the observed clinical phenotype (Liang et al., 2006). G35
is only conserved among the SCN5A orthologs, but not within
the Nav1 subfamily (Figure 1), which may suggest that G35S is a
variant rather than a mutation. However, G35S was not found in
100 controls and, paradoxically, the clinical features of the respec-
tive patient were more severe than those seen in case of R104Q
carriers (Levy-Nissenbaum et al., 2001).
POSSIBLE REASONS FOR THE OBSERVED GENOTYPE-PHENOTYPE
DISASSOCIATIONS
When analyzing the N-terminally mutated cardiac Na+ channels,
we noticed dramatic differences between both expression systems.
Channel defects were mainly seen in the mammalian system, but
not in frog oocytes. Such expression system differences have been
occasionally reported (Baroudi et al., 2000). However, it seems
that this is rather the exception than the rule, and despite tech-
nical limitations of the oocyte system, like variations in oocyte
quality and clamp properties, similar data have been observed for
most of the hNav1.5 mutant channels. For example, an increased
persistent current in KPQ channels can be easily detected in
both Xenopus oocytes and HEK293 cells (see Table 1). Moreover,
in a previous study on nine SSS-related mutant channels, loss-
of-function features were similarly detected in both expression
systems (Gui et al., 2010). In some cases, even more severe loss-
of-function properties were associated with the oocyte system.
Interestingly, none of the SSS-related mutations localized to the
hNav1.5 N-terminus.
We suggest that the expression system differences in the
present study point to important cellular mechanisms or fac-
tors in cardiomyocytes that specifically control or modulate the
Na+ channel N-terminus. It has been shown that the cytoplas-
mic N-terminal domain of Nav1.6 is required for intracellular
transport to the plasma membrane, a process that is facilitated
by microtubule-associated protein Map1b (Sharkey et al., 2009;
O’Brien et al., 2012). Xenopus oocytes may not be equipped
with respective protein quality control mechanisms, in contrast
to HEK293 cells that may accommodate some of those molec-
ular components. To provide evidence for this hypothesis, the
N-terminally mutated variants have to be expressed in cardiomy-
ocytes, similarly as done for D1275N channels by Watanabe
and co-workers recently (Watanabe et al., 2011). The authors
found near-normal currents upon heterologous expression of
D1275N, but striking in vivo effects in mice carrying one D1275N
allele. Similarly, E1053K channels were efficiently targeted to the
plasma membrane in HEK293 cells and produced robust cur-
rents. The ankyrin-binding motif abolished by this mutation was
not required for a successful expression in this cellular system.
In cardiomyocytes, however, mutant channels were nearly absent
from T-tubules and intercalated discs, and expression at the cell
surface was strongly reduced (Mohler et al., 2004).
Other pathogenic mechanisms in monogenetic ion chan-
nel diseases, apart from defective trafficking or ankyrin bind-
ing, could be an acidic intracellular pH (Wang et al., 2007),
increased temperature (Keller et al., 2005), or impaired chan-
nel expression from the wild-type and/or the mutated allele
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(Shang and Dudley, 2005; Leoni et al., 2010; Atack et al., 2011).
Moreover, we and others have demonstrated that the cellular
splicing machinery is a player affecting genotype-phenotype cor-
relations in cardiac diseases (Shang et al., 2007; Walzik et al., 2011;
Murphy et al., 2012). It is possible that some mutant channels
investigated in this study show normal electrophysiological fea-
tures in the background of the wild-type sequence, but altered
properties upon an alternative splicing event, similarly as shown
previously for T1620K (Walzik et al., 2011). Genetic testing for
the diagnosis of SCN5A channelopathies does not include anal-
ysis of the patients’ mRNA, and consequently, possible splicing
alterations can not be detected. It is intriguing to speculate that
an abnormal splicing could be caused by a pathological alteration
of the splicing machinery itself, leading to an excision of impor-
tant SCN5A exons, to the alternative usage of neonatal exon 6a
instead of adult exon 6b, or even to an alternative exon usage
in another cardiac ion channel. This could result in ion channel
defects also in the absence of any ion channel mutation, and thus
explain why nearly 80% of all BrS patients are SCN5A-negative
cases. We think that this is a fascinating idea worth to be tested in
the future.
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